Atea Pharmaceuticals, Inc.

AVIR

Held by 3 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

3 funds opened new positions. Next phase3 readout (Bemnifosbuvir-Ruzasvir (BEM/RZR)): Sep 2026. Short interest: 12.7% of float.

Catalysts

Phase 2Q1 2020AT-527Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis CNCT04019717

Primary: Proportion of subjects achieving sustained virologic response (SVR) (12 weeks after end of treatment)Enrollment:10/10Sites: 3NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ1 2022AT-527COVID-19NCT04396106

Primary: Proportions (Active vs. Placebo) of Subjects With Progressive Respiratory Insufficiency (PRI) on or Before Day 14. (Day 14)Enrollment:83/83Sites: 37RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2022AT-777Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis CNCT04309734

Primary: Incidence of Treatment-Emergent Adverse Events (Through Day 6 for subjects in Part A)0Sites: 1RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeQ1 2023AT-752Dengue FeverNCT05466240

Primary: Change in Dengue (DENV) Viral Load From Baseline (Baseline, Day 2, Day 3, Day 4, Day 5, Day 6, Day 8, Day 14, Day 28)Enrollment:21/21Sites: 32RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q2 2024Bemnifosbuvir (BEM)Severe Acute Respiratory Syndrome Coronavirus 2 (SARS Co V 2 Infection), COVID-19NCT05629962

Primary: Percentage of Subjects Hospitalized for Any Cause or Died Due to Any Cause (Day 1 through Day 29)Enrollment:2,285/2,285Sites: 263RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q4 2024BemnifosbuvirChronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis CNCT05904470

Primary: Percentage of Subjects Achieving Sustained Virologic Response at 12 Weeks Post-treatment (SVR12) (Day 1 through 12 weeks after end of treatment)Enrollment:275/275Sites: 51NA, TREATMENT

Phase 3Q3 2026Bemnifosbuvir-Ruzasvir (BEM/RZR)HEPATITIS C VIRUS CHRONIC INFECTIONNCT06868264

Primary: Proportion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at study week 24. (Day 1 through Week 24)Enrollment:Target 880Sites: 105RANDOMIZED, SINGLE, TREATMENT

Phase 3Q4 2026Bemnifosbuvir-RuzasvirHEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus InfectionNCT07037277

Primary: Portion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at week 24 (Day 1 through Week 24)Enrollment:Target 880Sites: 107RANDOMIZED, SINGLE, TREATMENT

Atea Pharmaceuticals, Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research